Optimal bone health management strategies in patients with prostate cancer.

5.8%) and a nonsignificant trend toward higher ONJ (2.3% vs. 1.3%; P = 0.09).[ 49 ] An improved efficacy of Denosumab compared with Bisphosphonates was also reported in a phase II trial of patients with multiple tumor types – PCa (45%), breast cancer (40%), and other tumors (15%).[ 50 ] Further analysis of a subset of patients with PCa ( n = 50) from this trial revealed the superiority of Denosumab compared with Bisphosphonates for normalization of bone turnover based on urinary biomarkers.[ 51 ] This was achieved in 69% of patients in the denosumab group and in only 19% of patients in the bisphosphonate group.

also in 5,406 other papers